World's First HPV Genotyping & Normalized Quantification Assay: Clinical Breakthroughs and Evidence-Based Impact
As the world’s first developer of the HPV Genotyping & Normalized Quantification Assay, BioPerfectus cordially invites you to join our exclusive webinar and witness this transformative breakthrough in cervical cancer prevention.June 19, 2025, 11:30 AM (UTC)Register NowNext-Gen Cervical Screening: Integrating Genotyping with Viral LoadDespite decades of progress, cervical cancer remains a leading cause of cancer-related deaths among women globally. Traditional screening methods struggle to balance underscreening gaps and overtreatment risks—a dilemma now addressed by genotype-specific viral load quantification.Cervical cancer screening is evolving from the qualitative "positive/negative" paradigm to a precision-driven era of genotyping paired with standardized viral load quantification—a dual-strategy approach that redefines clinical decision-making.Global Guidelines InsightConsensus on HPV viral load standardization from leading guidelines.Cutting-Edge Technology21 HPV genotype detection + single-copy gene-based normalized quantification.Evidence-Driven ValidationProof from clinical studies, aligned with international standards.Critical Clinical ValueRole of HPV viral load in cervical lesion risk stratification, treatment efficacy tracking, and prognosis monitoring.Agenda Highlights:11:30 – 11:40 UTC: Welcome & Agenda Overview11:40 – 12:25 UTC: Expert Talk: Global Trends in HPV Diagnostics12:25 – 12:35 UTC: Solution Showcase + Genotyping & Quantification Demo12:35 – 12:50 UTC: Live Q&A Session – Ask the Experts!About the Speaker: Prof. Pengming Sun, MD, PhD, a globally recognized leader in HPV detection and cervical cancer prevention.
